The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Targeting PI3K/mTOR Signaling in Cancer
Open accessAbstract
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,139
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61742-x · Cited by 1,058
Regulation and function of mTOR signalling in T cell fate decisions
Chi, H. (2012) · Nature Reviews Immunology · doi:10.1038/nri3198 · Cited by 1,035
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
SEHGAL, S. N., BAKER, H., & VÉZINA, C. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.727 · Cited by 947
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Liang, J., & Slingerland, J. M. (2003) · Cell Cycle · doi:10.4161/cc.2.4.433 · Cited by 885
Bissler, J. J., Kingswood, J. C., Radzikowska, E., Zonnenberg, B. A., Frost, M., Belousova, E., Sauter, M., Nonomura, N., Brakemeier, S., de Vries, P. J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61767-x · Cited by 880
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794
Protein–protein interactions define specificity in signal transduction
Pawson, T., & Nash, P. (2000) · Genes & Development · doi:10.1101/gad.14.9.1027 · Cited by 780
PTEN: Life as a Tumor Suppressor
Simpson, L., & Parsons, R. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 679
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649
Yao, J. C., Lombard-Bohas, C., Baudin, E., Kvols, L. K., Rougier, P., Ruszniewski, P., Hoosen, S., St. Peter, J., Haas, T., Lebwohl, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2669 · Cited by 647
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Akt-dependent and -independent mechanisms of mTOR regulation in cancer
Memmott, R. M., & Dennis, P. A. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.01.004 · Cited by 382
Autophagy is a therapeutic target in anticancer drug resistance
Chen, S., Rehman, S. K., Zhang, W., Wen, A., Yao, L., & Zhang, J. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.003 · Cited by 341
Lu, Y., Lin, Y.-Z., LaPushin, R., Cuevas, B., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T., Mao, M., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1203183 · Cited by 322
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee, C., Pandey, S. K., Nwokorie, C., Onwudiwe, N., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204736 · Cited by 298
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
Terris, Scoazec, Rubbia, Bregeaud, Pepper, Ruszniewski, Belghiti, FLÉjou, & Degott (1998) · Histopathology · doi:10.1046/j.1365-2559.1998.00321.x · Cited by 279
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
Logue, J. S., & Morrison, D. K. (2012) · Genes & Development · doi:10.1101/gad.186965.112 · Cited by 250
Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5766 · Cited by 245
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Abdollahi, A., & Folkman, J. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.12.001 · Cited by 233
Akt inhibitors in clinical development for the treatment of cancer
Pal, S. K., Reckamp, K., Yu, H., & Figlin, R. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.520701 · Cited by 226
Yao, J. C., Pavel, M., Phan, A. T., Kulke, M. H., Hoosen, S., St. Peter, J., Cherfi, A., & Öberg, K. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0666 · Cited by 225
Hidalgo, M., Buckner, J. C., Erlichman, C., Pollack, M. S., Boni, J. P., Dukart, G., Marshall, B., Speicher, L., Moore, L., & Rowinsky, E. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0118 · Cited by 212
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease
Astrinidis, A., & Henske, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1209090 · Cited by 209
Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., & Seufferlein, T. T. W. (1999) · PubMed · Cited by 209
AKT crystal structure and AKT-specific inhibitors
Kumar, C. C., & Madison, V. (2005) · Oncogene · doi:10.1038/sj.onc.1209087 · Cited by 206
New antitumor substances of natural origin
Douros, J., & Suffness, M. (1981) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(81)80006-0 · Cited by 202
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors
Sommer, E. M., Dry, H., Cross, D. A. E., Guichard, S. M., Davies, B. R., & Alessi, D. R. (2013) · Biochemical Journal · doi:10.1042/bj20130342 · Cited by 180
The Paradox of Akt-mTOR Interactions
Vadlakonda, L., Dash, A., Pasupuleti, M., Kumar, K. A., & Reddanna, P. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00165 · Cited by 169
Vadlakonda, L., Pasupuleti, M., & Pallu, R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00085 · Cited by 158
Hussain, A. R., Ahmed, S. O., Ahmed, M., Khan, O. S., Abdulmohsen, S. A., Platanias, L. C., Al-Kuraya, K. S., & Shahab Uddin, M. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039945 · Cited by 154
Léonard, R., Hardy, J. R., van Tienhoven, G., Houston, S., Simmonds, P., David, M., & Mansi, J. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4150 · Cited by 147
Tan, J. Y., Lee, P. L., Li, Z., Jiang, X., Lim, Y. C., Hooi, S. C., & Yu, Q. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.021 · Cited by 146
Porta, C., Osanto, S., Ravaud, A., Climent, M. Á., Vaishampayan, U. N., White, D. A., Creel, P. A., Dickow, B., Fischer, P., Gornell, S., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.02.014 · Cited by 146
Calvo, E., Escudier, B. J., Motzer, R. J., Oudard, S. M., Hutson, T. E., Porta, C., Sergio Bracarda, A., Grünwald, V., Thompson, J. A., Ravaud, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.11.027 · Cited by 130
Martelli, A. M., Chiarini, F., Evangelisti, C., Cappellini, A., Buontempo, F., Bressanin, D., Fini, M., & McCubrey, J. A. (2012) · Oncotarget · doi:10.18632/oncotarget.477 · Cited by 123
Targeting PI3K in Cancer: Any Good News?
Martini, M., Ciraolo, E., Gulluni, F., & Hirsch, E. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00108 · Cited by 123
Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Chen, Y., Law, P. C., & Loh, H. H. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/156801105774574649 · Cited by 113
Porta, C., & Figlin, R. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.08.085 · Cited by 110
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
Weigelt, B., & Downward, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00109 · Cited by 102
mTOR as a Positive Regulator of Tumor Cell Responses to Hypoxia
Abraham, R. T. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-18930-2_18 · Cited by 98
Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications
Scoazec, J. (2012) · Neuroendocrinology · doi:10.1159/000338371 · Cited by 95
Villaume, K., Blanc, M., Gouysse, G., Walter, T., Couderc, C., Nejjari, M., Vercherat, C., Cordier–Bussat, M., Roche, C., & Scoazec, J. (2010) · Neuroendocrinology · doi:10.1159/000289569 · Cited by 92
Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience
Yao, J. C., Phan, A. T., Jehl, V., Shah, G., & Meric‐Bernstam, F. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3923 · Cited by 90
S6K2: The Neglected S6 Kinase Family Member
Pardo, O. E., & Seckl, M. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00191 · Cited by 78
Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma
Rosich, L., Xargay‐Torrent, S., López‐Guerra, M., Campo, E., Colomer, D., & Roué, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0351 · Cited by 75
p110δ PI3 kinase pathway: emerging roles in cancer
Tzenaki, N., & Papakonstanti, E. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00040 · Cited by 68
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
Fox, E. M., Arteaga, C. L., & Miller, T. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00145 · Cited by 59
Fedele, P., Calvani, N., Marino, A., Orlando, L., Schiavone, P., Quaranta, A., & Cinieri, S. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.03.004 · Cited by 55
Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy
Tan, J. Y., & Yu, Q. (2013) · 癌症:英文版 · doi:10.5732/cjc.012.10287 · Cited by 47
Ribatti, D. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.02.002 · Cited by 39
Did We Get Pasteur, Warburg, and Crabtree on a Right Note?
Vadlakonda, L., Dash, A., Pasupuleti, M., Kumar, K. A., & Reddanna, P. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00186 · Cited by 17
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
NRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
Metadata
- Authors
- Arcaro, A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014-04-22
- Volume
- 4
- Pages
- 84-84
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2017181626
- Cited by
- 1,024
- References
- 75
- FWCI
- 27.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.